1 INTRODUCTION OF JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET (2025-2033)

1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY: JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET (2025-2033)

3 RESEARCH METHODOLOGY (2025-2033)

3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS

4 JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET OUTLOOK (2025-2033)

4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ​​ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE

5 JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET, By Disease Type (2025-2033)

5.1 OVERVIEW
5.2 CMT 1
5.3 CMT 2
5.4 CMT 3
5.5 Other

6 JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET, By Drug Type (2025-2033)

6.1 OVERVIEW
6.2 Nonsteroidal anti-inflammatory drugs
6.3 Cyclooxygenase-2 inhibitors
6.4 Tricyclic antidepressants
6.5 Anticonvulsants
6.6 Analgesics
6.7 Pipeline Drug

7 JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET, By surgery (2025-2033)

7.1 OVERVIEW
7.2 Soft-tissue procedures
7.3 Osteotomy
7.4 Joint-stabilizing procedures

8 JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET, By Distribution Channel (2025-2033)

8.1 OVERVIEW
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies

9 JAPAN CHARCOT-MARIE-TOOTH DISEASE (CMT) THERAPEUTICS MARKET COMPETITIVE LANDSCAPE (2025-2033)

9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES

10 COMPANY PROFILES (2025-2033)

10.1 Addex Therapeutics Ltd.
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
101.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.2 Affectis Pharmaceuticals AG
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.3 Genzyme Corp.
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.4 Lead Discovery Center GmbH
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.5 Pharnext SA
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.6 Acceleron Pharma
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

10.7 MedDay Pharmaceuticals
10.8 Bristol-Myers-Squibb Company
10.9 Inflectis Bio Science Health Company
10.10 Helixmith Co., Ltd.
10.11 Neurogene Inc.